Список проголосовавших за комментарий " Rite Aid beats by $0.08, beats on revs (3.73)<ul><li>Reports Q4 (Feb) adj. EPS $0.00, <strong>$0.08 <span style="color:#228822;">better than</span></strong> the two analyst estimate of ($0.08); revenues rose 3.3% year/year to $8.54 bln vs the $8.26 bln Capital IQ Consensus. Retail Pharmacy Segment revenues were $7.1 billion and increased 4.3% compared to the prior year period primarily as a result of the extra week in the fourth quarter, partially offset by a decrease in same store sales. Revenues in the company's Pharmacy Services Segment were $1.5 billion and decreased 1.3% compared to the prior year period.</li><li>Same store sales for the quarter decreased 3.0% over the prior year, consisting of a 4.3% decrease in pharmacy sales and a 0.3% decrease in front-end sales.</li><li>From Jan 30: <strong>WBA</strong> and Rite Aid agreed to reduce the price for each share of Rite Aid common stock to be paid by WBA. In addition, WBA will be required to divest up to 1,200 Rite Aid stores and certain additional related assets if required to obtain regulatory approval. The exact per share merger consideration will be determined based on the number of retail stores that WBA agrees to divest in connection with the parties' efforts to obtain the required regulatory approvals for the merger, with the price set at $7.00 per share if 1,000 retail stores or fewer retail stores are required to be divested and at $6.50 per share if 1,200 retail stores are required to be divested (or more, if WBA agrees to sell more). Additionally, WBA and Rite Aid agreed to extend the end date to July 31, 2017.</li></ul>"